China Resources Boya Bio pharmaceutical Group Co Ltd Asset Resilience Ratio
China Resources Boya Bio pharmaceutical Group Co Ltd asset resilience ratio. China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has an Asset Resilience Ratio of 23.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of China Resources Boya Bio pharmaceutical to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of China Resources Boya Bio pharmaceutical Group Co Ltd (2015–2025)
Asset resilience ratio of China Resources Boya Bio pharmaceutical Group Co Ltd from 2015 to 2025. This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Read China Resources Boya Bio pharmaceutical (300294) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see China Resources Boya Bio pharmaceutical assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.95 Billion | 23.15% |
| Total Liquid Assets | CN¥1.95 Billion | 23.15% |
Asset Resilience Insights
- Good Liquidity Position: China Resources Boya Bio pharmaceutical Group Co Ltd maintains a healthy 23.15% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
China Resources Boya Bio pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare China Resources Boya Bio pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
China Resources Boya Bio pharmaceutical Group Co Ltd Asset Resilience Ratio by Year (2015–2025)
China Resources Boya Bio pharmaceutical Group Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for China Resources Boya Bio pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.79% | CN¥2.66 Billion ≈ $388.79 Million |
CN¥8.63 Billion ≈ $1.26 Billion |
+4.61pp |
| 2024-12-31 | 26.18% | CN¥2.20 Billion ≈ $321.80 Million |
CN¥8.40 Billion ≈ $1.23 Billion |
-16.77pp |
| 2023-12-31 | 42.95% | CN¥3.36 Billion ≈ $492.03 Million |
CN¥7.83 Billion ≈ $1.15 Billion |
+3.19pp |
| 2022-12-31 | 39.76% | CN¥3.19 Billion ≈ $467.37 Million |
CN¥8.03 Billion ≈ $1.18 Billion |
+4.33pp |
| 2021-12-31 | 35.42% | CN¥2.70 Billion ≈ $395.09 Million |
CN¥7.62 Billion ≈ $1.12 Billion |
+33.36pp |
| 2016-12-31 | 2.07% | CN¥50.00 Million ≈ $7.32 Million |
CN¥2.42 Billion ≈ $354.05 Million |
+1.15pp |
| 2015-12-31 | 0.91% | CN¥20.00 Million ≈ $2.93 Million |
CN¥2.19 Billion ≈ $320.20 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more